Medpace Holdings, Inc.
NASDAQ:MEDPMedical - Diagnostics & Research
-$4.51 today
- Market cap
- $18.09B
- Beta
- 1.18
- P/E (TTM)
- 28.2
- EPS (TTM)
- $16.19
Volume 0.21M
Average 0.36M
MEDP Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Medpace Holdings, Inc.NASDAQ: MEDP
Gross Profit · Q3 FY2026 · quarter ended Sep 2026
Gross profit grows in line with its trailing trend
Q3 FY2026 gross profit of $223.89M rose 13.7% year over year, ahead of the +12.8% change in trailing-twelve-month gross profit. Sequentially, it rose 11.0% from the prior quarter. Over 3 fiscal years it compounded at +20.7% a year.
Context
- Gross profit amounted to 30.1% of revenue in FY2025, down 1.1 pp from a year earlier.
- Gross profit increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +13.7% holds above the trailing-twelve-month pace of +12.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 760.62M USD
- Year-over-year change
- +15.9%
- 4-year CAGR
- +23.4%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 760.62M | +15.9% |
| FY2024 | 2024-12-31 | 656.31M | +25.1% |
| FY2023 | 2023-12-31 | 524.51M | +21.3% |
| FY2022 | 2022-12-31 | 432.44M | +31.8% |
| FY2021 | 2021-12-31 | 328.16M | — |
Gross Profit vs competitors
How MEDP compares with its peers on the latest reported figures
- MEDP's LTM Sep 2026 gross profit of $827.16M is the 4th highest of the 5 companies compared; the peer median is $1.55B.
- Its year-over-year change of +12.8% is the highest of 5, against a peer median of -14.5%.
- Gross profit amounts to 29.1% of revenue for MEDP, versus a peer median of 24.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $4.46B | -17.1% | +2.6% | 26.2% | |
| LTM Jun 2026 | $1.8B | -22.0% | -0.6% | 21.8% | |
| LTM Jun 2026 | $1.29B | -1.4% | -5.7% | 32.2% | |
| LTM Sep 2026 | $827.16M | +12.8% | +20.7% | 29.1% | |
FTREFortrea Holdings Inc. | LTM Jun 2026 | $457.9M | -11.9% | -16.2% | 17.1% |
| Peer median (excluding MEDP) | $1.55B | -14.5% | -3.2% | 24.0% | |
Competitors are the stored peer set for MEDP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.14B | 1.46B | 1.89B | 2.11B | 2.53B |
| Cost of Revenue | 814.22M | 1.03B | 1.36B | 1.45B | 1.77B |
| Gross Profit | 328.16M | 432.44M | 524.51M | 656.31M | 760.62M |
| Gross Margin | 28.7% | 29.6% | 27.8% | 31.1% | 30.1% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 108.42M | 131.4M | 161.35M | 180.18M | 197.56M |
| Operating Expenses | 129.54M | 153.74M | 187.68M | 209.44M | 225.68M |
| Depreciation & Amortization | 21.12M | 22.34M | 26.33M | 29.25M | 28.12M |
| EBITDA | 223.08M | 308.11M | 362.5M | 505.17M | 570.5M |
| EBITDA Margin | 19.5% | 21.1% | 19.2% | 24.0% | 22.5% |
| Operating Income | 198.62M | 278.7M | 336.83M | 446.87M | 534.94M |
| Operating Margin | 17.4% | 19.1% | 17.9% | 21.2% | 21.1% |
| Interest Income | 0 | 0 | 0 | 25M | 0 |
| Interest Expense | 105K | 2.91M | 488K | 0 | 0 |
| Other Income / Expenses | 3.24M | 4.16M | (1.14M) | 29.05M | 7.44M |
| Income Before Tax | 201.85M | 282.86M | 335.68M | 475.92M | 542.38M |
| Pre-Tax Margin | 17.7% | 19.4% | 17.8% | 22.6% | 21.4% |
| Income Tax Expense | 20M | 37.49M | 52.87M | 71.54M | 91.25M |
| Net Income | 181.85M | 245.37M | 282.81M | 404.39M | 451.12M |
| Net Margin | 15.9% | 16.8% | 15.0% | 19.2% | 17.8% |
| EPS (Basic) | 5.06 | 7.57 | 9.20 | 13.06 | 15.64 |
| EPS (Diluted) | 4.81 | 7.28 | 8.88 | 12.63 | 15.28 |
| Weighted Avg Shares | 35.86M | 32.39M | 30.72M | 30.96M | 28.85M |
| Weighted Avg Shares (Diluted) | 37.7M | 33.67M | 31.84M | 32.01M | 29.53M |
Medpace Holdings, Inc.
NASDAQ:MEDP
Intrinsic Alpha fair value
Locked
Current Price
$646.87
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.